Schedule

Essential Diagnostics for Advanced HIV Disease

Venue: Hotel African, Kampala, Uganda

Date: 10th -12th April, 2018

Website: https://icahd2018.org/

                           PROGRAMME

Day 1: Tuesday 10th April 2018

 

Session 1: Moderator- David Denning

11:00    Introduction to GAFFI and meeting objectives – David Denning, GAFFI

11:25    Advanced HIV – putting the AIDS back in AIDS – Tom Chiller, CDC

11:50    A network model to diagnose opportunistic infections in persons living with HIV for LMICs– Juan Luis Rodriguez Tudela, GAFFI, Geneva

12:10    WHO advanced HIV disease guidelines – Chantal Migone, WHO

12:35    Workshop groups, timelines and tasks – David Denning

13:00 Lunch

13:45 Breakout sessions:

            A. Cryptococcal LFA – Leader: David Boulware, Minnesota

            B. Histoplasma antigen detection – Leader: Mathieu Nacher, French guinea

            C. Toxoplasma IgG detection – Leader: Florence Robert Gangneux,                                    Toxoplasma Reference Laboratory, Rennes

            D. Aspergillus IgG detection – Leader: Malcolm Richardson, Mycology Reference Laboratory, Manchester

15:15 break

15:45    Breakout group summaries and discussion – Discussion leader: Samson Haumba, University Research Co., LLC, Mbabane, Swaziland

Session 2: Moderator-Subramanian Swaminathan

17:00    The AIDS patient with a ‘neuro’ presentation – diagnostic considerations – Conrad Muzoora, Mbarara University of Science and Technology, Uganda

17:20    The AIDS patient with a ‘respiratory’ presentation – diagnostic considerations – William Worodria, Mulago Hospital, Kampala, Uganda

17:40    The AIDS patient with a ‘weight loss and decline’ presentation – diagnostic considerations – Felix Bongomin, Manchester UK.

18:00   Close – Welcome drinks

Day 2: Wednesday 11th April 2018

Session 3: Moderator-Nelesh P. Govender

9:00      How WHO PQ differs from CE marking and FDA 510K/PMA processes – Irena Prat, WHO, Geneva (Remote).

9:25      The importance of measuring CD4 count – Tom Chiller, CDC

9:50      Quality assurance systems for fungal and toxoplasma serology, microscopy, fungal culture and therapeutic antifungal drug monitoring – Jean Pierre Gangneux. Mycology and Parasitology, University of Rennes.

10:15    Discussion

11:00 Break

11:30    Breakout sessions:

            A. Cryptococcal antigen quantification – Leader: David Meya, Makerere                              University, Kampala

            B. Pneumocystis PCR – Leader: Jahit Sacarlal, Universidade Eduardo                                  Mondlane, Maputo, Mozambique

            C. Azole drug monitoring – Leader: Alessandro Pasqualotto, Porte Alegre, Brazil

            D. TB LAM Ag – Leader: Tom H Boyles, University of the Witwatersrand, SA

13:00 Lunch

13:45    Breakout group summaries and discussion – Discussion leader: Ana Alastruey-Izquierdo, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain

15:15 Break

Session 4: Moderator- Rita O. Oladele

15:45    The summary case for inclusion as Essential Diagnostics (12 mins each):

            1. Direct microscopy – Charlotte Sriruttan NICD, Johannesburg, SA

            2. Glucan detection – Taminori Obayashi, Higashi Saitama General Hospital, Saitama, Japan

            3. Blood culture (bacterial, mycobacterial and fungal) – Afia Zafar, Aga Khan University, Karachi, Pakistan

4. Aspergillus antigen detection – David Denning, GAFFI   

            5. Bacterial culture – Joel Bazira, Mbarara University of Science and Technology, Uganda

            6. Fungal culture – Arunaloke Chakrabarti, WHO Collaborating Centre for medical Mycology, Chandigarh, India

17:00    Discussion – How should WHO EDL group handle these tests? Discussion leader -David Denning

18:00 Close

Day 3: Thursday 12th April 2018

Session 5: Moderator -Andrew Kambugu

8:30      Empiric therapy or diagnosis – how to minimize unnecessary antimicrobial exposure and corticosteroids – Alessandro Pasqualotto, Porte Alegre, Brazil

First session

8:55      Why each test should be included on the EDL (15 mins + 10 mins discussion)

Discussion leader

            A. Cryptococcal LFA – David Boulware

            B. Cryptococcal antigen quantification –David Meya

            C. Histoplasma antigen detection –Tom Chiller

            D. Pneumocystis PCR –Jahit Sacarlal

10:15    Session summary: Lara Vojnov, WHO, Geneva.

11:00 Break

Session 6: Moderator-Ben Chang

Second session

11:30    Why each test should be included on the EDL (15 mins + 10 mins discussion)

Discussion leader:

            E. Toxoplasma Ig detection –Florence Robert Gangneux

            F. Aspergillus IgG detection – Malcolm Richardson

            G. TB LAM Ag – Tom H Boyles

            H. Azole drug monitoring – Alessandro Pasqualotto, Porte Alegre, Brazil

12:30    Session summary: Arunaloke Chakrabarti, Chandigarh.

12:45    Wrap up – next steps

13:00 Lunch

Final Agenda- Essential Diagnostic for Advanced HIV Disease Kampala Uganda